Recombinant Human Interferon-lambda1/Interleukin-29
IL-28A, IL-28B, and IL-29, also named interferon-λ2 (IFN-λ2), IFN-λ3, and IFN-λ1, respectively, are newly identified class II cytokine receptor ligands that are distantly related to members of the IL-10 family (11-13 % a.a. sequence identity) and the type I IFN family (15-19 % a.a. sequence identity). The expression of IL-28A, B, and IL-29 is induced by virus infection or double-stranded RNA. All three cytokines exert bioactivities that overlap those of type I IFNs, including antiviral activity and up-regulation of MHC class I antigen expression. The three proteins signal through the same heterodimeric receptor complex that is composed of the IL-10 receptor β (IL-10 Rβ) and a novel IL-28 receptor α (IL-28 Rα, also known as IFN-λR1). Ligand binding to the receptor complex induces Jak kinase activation and STAT1 and STAT2 tyrosine phosphorylation.
Reference
1. Miller EK, Hernandez JZ, Wimmenauer V, et al. 2012. Am J Respir Crit Care Med, 185: 508-16
2. Li Y, Xie J, Xu X, et al. 2012. Protein Cell, 3. Jordan WJ, Eskdale J, Srinivas S, et al. 2007. Genes Immun, 8: 254-61
4. Pekarek V, Srinivas S, Eskdale J, et al. 2007. Genes Immun, 8: 177-80
5. Megjugorac NJ, Gallagher GE, Gallagher G. 2010. Blood, 115: 4185-90.
| Gene ID | 282618 |
| Accession # | Q8IU54 |
| Alternate Names | Cytokine Zcyto21 |
| Source | Escherichia coli. |
| M.Wt | Approximately 19.8 kDa, a single non-glycosylated polypeptide chain containing 181 amino acids. |
| AA Sequence | GPVPTSKPTT TGKGCHIGRF KSLSPQELAS FKKARDALEE SLKLKNWSCS SPVFPGNWDL RLLQVRERPV ALEAELALTL KVLEAAAGPA LEDVLDQPLH TLHHILSQLQ ACIQPQPTAG PRPRGRLHHW LHRLQEAPKK ESAGCLEASV TFNLFRLLTR DLKYVADGNL CLRTSTHPES T |
| Appearance | Sterile Filtered White lyophilized (freeze-dried) powder. |
| Stability & Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. - 12 months from date of receipt, -20 to -70 °C as supplied. - 1 month, 2 to 8 °C under sterile conditions after reconstitution. - 3 months, -20 to -70 °C under sterile conditions after reconstitution. |
| Formulation | Lyophilized from a 0.2 μm filtered concentrated solution in PBS, pH 7.4. |
| Reconstitution | We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤ -20 °C. Further dilutions should be made in appropriate buffered solutions. |
| Biological Activity | Fully biologically active when compared to standard. The ED50 as determined by an anti-viral assay using human HepG2 cells infected with encephalomyocarditis is less than 5 ng/ml, corresponding to a specific activity of > 2.0 × 105IU/mg. |
| Shipping Condition | Gel pack. |
| Handling | Centrifuge the vial prior to opening. |
| Usage | For Research Use Only! Not to be used in humans. |
Quality Control & DataSheet
- View current batch:
-
Purity > 97 % by SDS-PAGE and HPLC analyses.
- Datasheet
Endotoxin: Less than 1 EU/μg of rHuIFN-λ1/IL-29 as determined by LAL method.